About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 1140 record(s)
Req # A-2022-000972
Adverse Drug Reaction (ADR). Report number: E2B_05529290.Organization: Health Canada
January 2023
Req # A-2022-000977
Adverse Drug Reaction (ADR). Report number: E2B_05647389.Organization: Health Canada
January 2023
Req # A-2022-000985
Adverse Drug Reactions (ADRs) for . Report numbers: E2B_05162489, 001000230.Organization: Health Canada
January 2023
Req # A-2022-000987
Adverse Drug Reactions (ADRs) for Zenhale. Report numbers: E2B_00037157, E2B_00356618, E2B_01322347, E2B_01490363, E2B_01388080, E2B_01401854, E2B_01413472, E2B_01430853, E2B_01443157, E2B_01494497.Organization: Health Canada
January 2023
Req # A-2022-000989
Adverse Drug Reaction (ADR). Report number: E2B_05593659.Organization: Health Canada
January 2023
Req # A-2022-001000
Adverse Drug Reactions (ADRs). Report numbers: 001005965, E2B_04565185.Organization: Health Canada
January 2023
Req # A-2022-001002
Adverse Drug Reaction (ADR) for MEZAVANT. Report number: E2B_05680477. ADRs for Mesalazine. Report numbers: 001006029, 001006464, E2B_05628348, E2B_05643268. ADRs for VYVANSE. Report numbers: 001005158, E2B_05661529, 001005967. ADRs for GAMMAGARD…Organization: Health Canada
January 2023
Req # A-2022-001004
Adverse Drug Reactions (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_05697513, E2B_05662863, E2B_05676847. ADRs for Immunoglobulin (human). Report numbers: E2B_05654955, E2B_05650332, E2B_05626265, E2B_05638123, E2B_05675217. ADR for…Organization: Health Canada
January 2023
Req # A-2022-001005
Adverse Drug Reaction (ADR) for Dexilant. Report number: E2B_05679330. ADR for Entyvio. Report number: E2B_05636147. ADRs for Vedolizumab. Report numbers: E2B_05710173, E2B_05621550, 001006464, E2B_05612446. ADR for Ixazomib. Report number:…Organization: Health Canada
January 2023
Req # A-2022-001009
Adverse Drug Reactions (ADRs) for BISACODYL AND DOCUSATE SODIUM. Report numbers: 001006655, 001006867, E2B_05628348, E2B_05657880, E2B_05628332.Organization: Health Canada
January 2023